Merck (MRK) vs Novartis (NVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Merck (MRK) has outperformed Novartis (NVS) over the past year, gaining 36.8% versus a gain of 18.2%. Over five years, NVS leads with a +86.5% price change compared with +68.9% for MRK. Merck is the larger company by market cap ($329.65 billion vs $284.18 billion), about 1.2 times the size.
On valuation, Merck trades at a lower forward P/E (14.9x vs 15.1x for Novartis). Novartis offers the higher dividend yield (3.10% vs 2.51%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRK | NVS |
|---|---|---|
| Share price | $133.72 | $150.47 |
| Market cap | $329.65B | $284.18B |
| 1-day change | +0.69% | -0.50% |
| YTD return | +27.04% | +9.14% |
| 1-year return | +36.78% | +18.19% |
| 5-year return | +68.92% | +86.46% |
| P/E ratio (TTM) | 135.07 | 28.72 |
| Forward P/E | 14.92 | 15.15 |
| EPS (TTM) | $0.99 | $5.24 |
| Dividend yield | 2.51% | 3.10% |
| Annual dividend | $3.36 | $4.67 |
| Revenue (latest FY) | $65.01B | — |
| Revenue growth (YoY) | +1.31% | — |
| Net income (latest FY) | $18.25B | $13.98B |
| Gross margin | 74.80% | — |
| Net margin | 28.08% | — |
| 52-week high | $156.92 | $170.46 |
| 52-week low | $96.06 | $126.50 |
| Distance from 52-week high | -14.78% | -11.73% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +20.80% | +4.41% |
| Average volume | 9.81M | 2.18M |
| Shares outstanding | 2.47B | 1.89B |
| Employees | 73,000 | 75,267 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRK has outperformed NVS by 18.6 percentage points over the past year.
- Merck trades at a higher earnings multiple (135.1x vs 28.7x trailing P/E).
About Merck
MRK stock →Merck & Co., Inc. operates as a healthcare company worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees
About Novartis
NVS stock →Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees
MRK vs NVS FAQ
Which is bigger, Merck or Novartis?
Merck (MRK) is larger, with a market capitalization of $329.65B compared with $284.18B for Novartis (NVS).
Which stock has performed better over the past year, MRK or NVS?
MRK returned +36.78% over the past 12 months, compared with +18.19% for NVS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MRK or NVS?
NVS has the lower trailing P/E at 28.7, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Merck or Novartis?
Novartis has the higher yield at 3.10%, compared with 2.51% for Merck.
Are Merck and Novartis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.